Aptevo net loss widens to $13.1 million in FY26 H1; operating cash outflow narrows to $13.4 millionPUBT·Aug 14 at 07:16 AMAPVO-2.90%
Aptevo wins $1.5 million CARE Fund grant for APVO451 IND-enabling workPUBT·Aug 14 at 07:10 AMAPVO-2.90%
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results | APVO Stock NewsStockTitan·Aug 13 at 11:05 PMAPVO-2.90%
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds | APVO Stock NewsStockTitan·Aug 12 at 12:30 AMAPVO-2.90%
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone | APVO Stock NewsStockTitan·Jul 26 at 11:05 PMAPVO-2.90%
Aptevo targets solid tumors with planned Nectin-4 x PD-L1 dual-targeting platform strategyPUBT·Jul 27 at 03:12 PMAPVO-2.90%
